Phase 4 N=19 Buprenorphine and Methadone for Opioid-dependent Chronic Back Pain Patients
Low Back Pain
Primary: Analgesia — 36.3; 71.8 units on a VAS scale — p=0.097
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=12 Oxytocin Treatment of Opioid Dependence
Opioid Dependence · Opioid Withdrawal
Primary: Area Under the Curve (AUC) in COWS Total Score on Days 1 to 5 Inclusive — 4.2; 3.4 Average COWS score * hours
Phase 3 N=653 Prescription Opioid Addiction Treatment Study (POATS)
Opiate Dependence · Substance-related Disorders · Opioid-related Disorders
Primary: The Number of Participants Attaining Successful Opioid Use Outcome by Counseling Condition at End of Phase 1 — 19; 24 participants
N/A N=133 5HT3 Antagonists to Treat Opioid Withdrawal and to Prevent the Progression of Physical Dependence
Opioid Withdrawal · Physical Dependence
Primary: Change in Objective Opioid Withdrawal Score (OOWS) From Baseline (Prevention of Opioid Withdrawal) — 3.6; 3.6 units on a scale — p=0.87
Phase 2 N=51 Prescription Opioid Abuse Among Pain Patients: Predictors of Relapse
Opioid Dependence
Primary: Number of Participants Retained in Study — 18 participants
Phase 4 N=54 Buprenorphine and Methadone for Opioid Dependent Chronic Pain Patients
Opiate Addiction
Primary: Number of Participants Retained in Treatment — 13; 13 participants — p=0.77
Phase 4 N=12 A Comparison of the Addiction Liability of Hydrocodone and Sustained Release Morphine
Chronic Pain
Primary: 3 Scores on the Addiction Research Center Inventory (ARCI) — 7.6; 5.4; 5.2; 3.3 scores on a scale
N/A N=87 Effectiveness of Opiate Replacement Therapy Administered Prior to Release From a Correctional Facility - 1
HIV Prevention · Opioid-Related Disorders
Primary: Treatment Engagement — 23; 11; 6 participants — p=<0.001
Phase 3 N=53 Efficacy of Extended Release Tramadol for Treating Prescription Opioid Withdrawal
Substance Withdrawal Syndrome
Primary: Subjective Opioid Withdrawal Total Adjective Score — 5.8; 7.7; 6.9 units on a scale
Phase 4 N=16 Evaluating the Safety of Acute Baclofen in Methadone-maintained Individuals With Opiate Dependence.
Addiction Opiate
Primary: Number of Participants With Dose Limiting Toxicities — 0; 0; 0; 0 participants
Phase 3 N=21 Neuroimaging Predictors of Relapse During Treatment for Opiate Dependence
Opioid Addiction
Primary: Changes in Resting State Disorganization Between Baseline and One Week by Person by Lapsed Category — 0.315; 0.328; 0.384; 0.394 Mean default mode network (DMN) z-scores
N/A N=115 Opioid Treatment and Recovery Through a Safe Pain Management Program
Depression · Opioid Use · Chronic Pain
Primary: Odds of Morphine Equivalent Daily Dose (MEDD) of Opioid Prescription >=50 mg — 0.209; 0.417; 0.185; 0.364 odds of prescription high dose — p=0.956
N/A N=10 Palonosetron and Hydroxyzine to Reduce Opioid Withdrawal
Substance-Related Disorders
Primary: OOWS Score — 3.5; 1.0; 0 units on a scale (OOWS Scale) — p=0.0001
N/A N=9 Aprepitant Effects on Oxycodone Response
Narcotic Abuse
Primary: Abuse Liability Proxy — 0.197; 0.483; 0.159; 7.678 units on a scale (points 0-100) — p=<.05
Phase 3 N=74 Smoking Cessation & Opioid Dependence Treatment Integration
Smoking Cessation · Opioid Related Disorders
Primary: Recruitment, Assignment to Treatment, and Retention Rates — 40; 33; 15; 32 Participants
Phase 3 N=117 Improving Treatment Outcomes for Prescription Opioid Dependence
Drug Dependence
Primary: Detoxification Phase: Changes in Percent of Illicit Opioid-positive Urine Samples Over Time — 35.0; 41.6 percentage of urine positive samples — p=0.77
Phase 3 N=306 Addiction Treatment in Russia: Oral vs. Naltrexone Implant
Heroin Dependence · Opioid-Related Disorders
Primary: Retention Without Relapse to Heroin Addiction (Measured at Month 6) — 54; 16; 11 Participants
Phase 3 N=49 Lorcaserin in Combination With XR-Naltrexone for Relapse Prevention in Opioid Use Disorder
Opioid-use Disorder
Primary: Proportion of Patients Successfully Inducted to Receive Naltrexone Injection — 12; 7 Participants
N/A N=190 Opioid Prescribing After Cesarean Delivery
Surgery · Opioid Use
Primary: Unused Opioids — 5; 10 oxycodone 5mg tablets
Phase 1 N=20 Oxytocin, Stress, Craving, Opioid Use Disorder
Opioid Use Disorder
Primary: Opioid Craving — 21.6; 22.4; 23.3; 23.4 score on a scale
N/A N=15 Functional Magnetic Resonance Imaging of Opioid Withdrawal in Healthy Human Volunteers
Substance-Related Disorders
Primary: Brain Regions With Increases or Decreases in Amplitude of Low Frequency Fluctuations (ALFF) Associated With Ondansetron Administration — 0.519; 0.562; 0.478; 0.486…
N/A N=119 Stress Response in Opioid Use Disorder
Opioid-use Disorder
Primary: Change in Negative Affect — 1.67; 1.25; 3.60 scores on a scale
Phase 2 N=28 Effects of Ibudilast on Oxycodone Self-administration in Opioid Abusers
Opioid Abuse · Opioid Dependence
Primary: Drug Self-administration Breakpoint — 347; 363; 1472; 43 Clicks on a computer mouse
Phase 2 N=81 Memantine and Naltrexone Treatment for Opioid Dependence
Opioid Dependence
Primary: Retention in Treatment — 7; 5; 6 participants — p=0.32
N/A N=78 Stress, Distress Intolerance, and Drug Dependence
Substance Dependence
Primary: Percentage of Positive Toxicology Swabs for Illicit Substances — 81.3; 79.1; 86.2; 82.3 percentage of positive toxicology screen
Phase 2 N=30 Cannabidiol Effects on Craving and Relapse Prevention in Opioid Use Disorder
Opioid-use Disorder
Primary: The Primary Endpoint Will be Safety and Tolerability of CBD. — 13; 4 participants
Phase 4 N=31 NAS Treatment - Opiate Versus Non-Opiate
Neonatal Abstinence Syndrome
Primary: Finnegan Neonatal Abstinence Scoring System — 7.5; 8.5; 6.6; 5.7 scores on a scale
N/A N=102 Optimizing Pregnancy and Treatment Interventions for Moms 2.0
Pregnancy, High Risk · Opioid-Related Disorders · Pregnancy Related
Primary: Opioid Use Disorder (OUD) and Other Substance Use Disorder (SUD) Treatment Linkage/Retention — -1.5; -8.8 Percentage of days
N/A N=29 Signs and Symptoms of Opioid-associated Iatrogenic Withdrawal in Critically Ill Adults
Substance Withdrawal Syndrome
Primary: Description of Signs and Symptoms of OIWS in Patients Who Scored Positive for Withdrawal Syndrome (OIWS) According to Diagnostic and Statistical Manual of Mental…
N/A N=104 Start Treatment and Recovery for Opioid Use Disorder
Opioid-use Disorder · Mental Disorder · Opioid Medication Assisted Treatment
Primary: Number of Participants With Self-reported Treatment Retention — 51 Participants